Document 0077
 DOCN  M9620077
 TI    Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients.
 DT    9602
 AU    Ozick LA; Jacob L; Comer GM; Lee TP; Ben-Zvi J; Donelson SS; Felton CP;
       Department of Medicine, Harlem Hospital Center, Columbia; University,
       College of Physicians and Surgeons, New York, New; York, USA.
 SO    Am J Gastroenterol. 1995 Nov;90(11):1978-80. Unique Identifier :
       AIDSLINE MED/96048752
 AB    OBJECTIVE: To determine the incidence of hepatotoxicity due to isoniazid
       and rifampin in inner-city patients with active tuberculosis. DESIGN: A
       hospital-based review of 70 consecutive in-patients in a 770-bed,
       inner-city hospital. The patient population is primarily
       African-American and Hispanic. METHODS: Fifty-eight men and 12 women
       were followed from 2-12 wk (median 4 wk). Patients had to be treated for
       at least 2 wk to be eligible for the study. Patients were excluded if
       they had been on any anti-tuberculous or any other hepatotoxic drug
       during the 2-month period before their hospitalization.
       Aminotransferases, alkaline phosphatase, bilirubin, and albumin were
       obtained at least every 2 wk. RESULTS: Hepatocellular toxicity, defined
       as AST and/or ALT greater than 200 IU/L, occurred in eight out of 70
       (11.4%) patients. The mean age of these patients was 38.9 yr (22-58 yr).
       Patients with AIDS were significantly more likely to develop
       hepatotoxicity than those with any other risk factor (p < 0.01).
       CONCLUSIONS: Baseline aminotransferases followed by monitoring may be
       necessary in AIDS patients.
 DE    Adult  Alanine Aminotransferase/BLOOD  Alcoholism/EPIDEMIOLOGY
       Antitubercular Agents/*ADVERSE EFFECTS/THERAPEUTIC USE  Aspartate
       Aminotransferase/BLOOD  AIDS-Related Opportunistic Infections/*DRUG
       THERAPY/EPIDEMIOLOGY/  MICROBIOLOGY  Enzyme Tests  Female  Hepatitis,
       Toxic/DIAGNOSIS/*EPIDEMIOLOGY  Human  Incidence  Isoniazid/*ADVERSE
       EFFECTS/THERAPEUTIC USE  Liver Function Tests  Male  New York
       City/EPIDEMIOLOGY  *Poverty Areas  Rifampin/*ADVERSE EFFECTS/THERAPEUTIC
       USE  Risk Factors  Time Factors  Tuberculosis, Pulmonary/*DRUG
       THERAPY/EPIDEMIOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).